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Neonates with congenital diaphragmatic hernia (COH) often suffer from respiratory insufficiency due
to lung hypoplasia and pulmonary hypertension. Artificial ventilation is frequently required, and this
leads to a high incidence of bronchopulmonary dysplasia. long-term follow-up studies have shown
persisting airway obstruction. To evaluate the long-term pulmonary sequelae in COH, we studied 40
COH patients of age 7 to 18 yr (median 11.7 yr) and 65 age-matched controls without COHand lung
hypoplasia who underwent similar neonatal treatment. Mild airway obstruction was found in both
groups with more peripheral airway obstruction in COH patients than in control subjects. Both groups
had normal TlC and single-breath carbon monoxide diffusion capacity (Oleo). COH patients had in-
creased residual volume (RV) and RV/TlC compared with controls. Increased airway responsiveness
to methacholine (MCH) was common but bronchoconstriction to inhaled metabisulfite (MBS) was
rare both in COHand control subjects. We conclude that this group of COHpatients has minor residual
lung function impairment. Mild airway obstruction and increased airway responsiveness to inhaled
MCH but not to MBS suggest that structural changes in distal airways are involved and not autonomic
nerve dysfunction. Both artificial ventilation in the neonatal period and residual lung hypoplasia seem
important determinants of persistent lung function abnormalities in COH patients. Iisselstiin H, nb-
boel D, Hop WIC, Molenaar IC, de longste IC. Long-term pulmonary sequelae In children with
congenital diaphragmatic hernia. AM J RESPIR CRIT CARE MED 1997;155:174-180.
The treatment of prematurely born neonates and children with
congenital anomalies has improved during the past 20 yr, owing
to more sophisticated artificial ventilation techniques and neo-
natal intensive care. This has resulted in better chances to sur-
vive, at the cost of considerable secondary morbidity, e.g., due
to bronchopulmonary dysplasia (1). Bronchopulmonary dysplasia
(BPD) is a chronic lung disease, which may occur following
artificial ventilation in the first weeks after birth. The patho-
genesis is multifactorial: barotrauma and high concentrations
of inspired oxygen are important (1, 2). The incidence of bron-
chopulmonary dysplasia is highest in prematurely born infants
with very low birth weight (2) (up to 85070). Long-term follow-up
of prematurely born neonates has revealed chronic obstructive
lung disease with increased airway responsiveness in adolescents
and young adults who required artificial ventilation in the neo-
natal period (3-9). Congenital diaphragmatic hernia (CDR) is
associated with a decreased number of airway generations, and
a decreased number of vascular generations (10). Furthermore,
pulmonary vascular abnormalities that lead to pulmonary hyper-
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tension have been described (11). Artificial ventilation with high
pressures and a high inspired oxygen fraction (F102) is often re-
quired in the neonatal period.
Bronchopulmonary dysplasia has been described in 33070 of
CDR survivors despite a mean birth weight of nearly 3,000 g
(12). Several follow-up studies found mild airflow obstruction
in CDR patients (13-15). Ventilation-perfusion lung scans show
diminished perfusion on the ipsilateral sideof the diaphragmatic
defect, suggesting residual vascular abnormalities in the most
hypoplastic lung (14-17). Data on airway responsivenessin CDR
are lacking. We hypothesized that children with CDR have an
increased risk to develop chronic lung disease and increased air-
way responsiveness in later life, and that the prevalence and
severity of lung function abnormalities might depend on initial
lung hypoplasia. The aim of this study was to evaluate the long-
term pulmonary sequelae in children with CDR and in age-
matched controls without CDR and lung hypoplasia who un-
derwent similar neonatal treatment.
METHODS
Patients
A group of 45 children survived neonatal operative repair of CDH in
our Department of Pediatric Surgery between 1975and 1986.Forty could
be traced and werewilling to participate Operative repair was performed
immediately after diagnosis of CDH in all patients using an abdominal
approach. Thirty-five children with left-sided CDH and one with right-
sided CDH had surgery within the first day of life. All patients rou-
tinely received antimicrobial prophylaxis perioperatively. Thirty-one chil-
dren suffered from severe respiratory insufficiency within the first 6 h
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after birth. Weattempted to select two age-matched control patients with-
out COH for each COH patient. The controls were selected from files
of the Neonatal and Pediatric Intensive Care Units of the Sophia Chil-
dren's Hospital in Rotterdam, and the Neonatal Intensive Care Units
of the Wilhelmina Children's Hospital in Utrecht and the Free Univer-
sity Hospital in Amsterdam. These control patients were all matched
for age at follow-up, and further selected to obtain the best possible
match for gestational age, birth weight, duration of artificial ventila-
tion, duration of supplemental oxygen, and sex. To be included in this
study the following criteria had to be met by all patients: (1) ability to
perform lung function tests reproducibly, that is, coefficient of varia-
tion in three consecutive measurements of FEV. < 50/0; (2) clinically
stable period of at least 3 wk prior to the lung function tests. Exclusion
criteria were:any previous thoracic surgery for other reasons than CDH;
(congenital) heart disease; lung hypoplasia following prolonged rupture
of membranes or renal anomalies with oligohydramnion, or other con-
genital or acquired disorders of the lungs or airways; inability to follow
study instructions; inability to inhale medication adequately. The study
was approved by the medical ethical committees of all hospitals involved.
Written informed consent was obtained from all parents.
Study Design
During a prestudy visit a detailed medical history, including personal
and family history of atopy and lung disease, was taken. Furthermore,
the parents wereasked to fill out a standardized questionnaire referring
to respiratory symptoms, consultation of physicians, and smoking habits.
Physical examination was performed including pulse, blood pressure,
respiratory rate, and auscultation of heart and lungs. 1\\'0 wk before
the lung function tests, daily peak flow measurements (Mini Wright Peak-
flowmeter; Airmed, Harlow, UK) wereperformed at home in the morn-
ing and evening (before taking medication if required), and recorded
on a daily record card. The highest value of three consecutive measure-
ments was used for further analysis. The symptoms cough, wheezing,
production of sputum, and dyspnea wererecorded daily. For each symp-
tom a score from 0 (absent) to three (severe) was given. In this way a
maximum score of 96 could be obtained within an 8-d period. The mean
diurnal variation of peak flow (which is the absolute difference between
morning and evening value divided by the mean value of morning and
evening x 100%) (18) and the total cumulative symptom score from
Day 8 to Day 15 were evaluated.
Lung function tests were performed on two separate days within a
l-wk period. Any medication was discontinued 12 h prior to the tests.
To avoid diurnal variation in the measurements, all tests were done in
the morning. Spirometry was performed on the first day between 9:00
and 11:00 A.M., and followed by an inhalation provocation test with
methacholine (MCH) when the baseline ratio of forced expiratory vol-
ume in one second to vital capacity (FEV./VC) was at least 0.7. One
hour later, when the baseline FEV. had returned to at least 90% of the
initial baseline, an inhalation provocation test with metabisulfite (MBS)
was performed. Methacholine is a bronchoconstrictor which acts directly
at airway smooth muscle, whereas MBS acts indirectly, probably via
neuronal pathways (19).On the second day, spirometry and volume-flow
curves were recorded before and after maximal bronchodilatation with
terbutaline to study reversibility of airway obstruction. Helium dilution
spirometry, body plethysmography, and single-breath carbon monox-
ide diffusion capacity (OLeo) were carried out after bronchodilatation
only.
Lung Function and Bronchial Provocation Tests
Spirometry was performed using a water-sealed spirometer (Volutest
Model VLT; Mijnhardt, Zeist, the Netherlands). FEV. and VC werede-
termined as the best of three reproducible measurements. Flow-volume
curves were obtained with a heated Fleisch pneumotachograph (Num-
ber 3.1184; Godart Statham, Bilthoven, the Netherlands) connected to
a computer. FEVt, FVC, peak expiratory flow (PEF), and maximal ex-
piratory flows at 25% of the FVC (MEFzs) were determined and the
best of three consecutive measurements was recorded and expressed as
percentage of predicted values (20).
Spirometry and flow-volume curves were performed before and 15
min after I mg of terbutaline sulfate, deliveredby turbuhaler (Astra Phar-
maceuticals, Lund, Sweden) as two inhalations of 500 J.l.g. After each
inhalation the breath was held for 5 s. The change, expressed as percent-
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age of predicted value, was calculated to evaluate reversibility of any
airflow obstruction.
A water-sealedspirometer (Expirograph; Godart Statham, Bilthoven,
the Netherlands) filled with a known concentration of helium was used
to determine TLCHe, residual volume of helium (RVHe), VCHe, tidal vol-
ume (TV), inspiratory reserve volume (lRV), and expiratory reserve vol-
ume (ERV). Helium was allowed to wash in for at least 5 min during
normal tidal breathing until a stable concentration wasobtained. Volumes
were expressed as percentage of the actual TLC. Specific conductance
of airways (SGaw), TLCpleth, RVpleth- and RV/TLC were determined by
body plethysmography (Jaeger Masterlab, Wiirzburg, Germany), and
the best of three consecutive measurements was recorded. All values,
except RV/TLC, wereexpressed as a percentage of predicted values (20).
Carbon monoxide diffusion capacity (Oleo) wasmeasured using a single-
breath method (Jaeger Masterlab, Wiirzburg, Germany). Referencevalues
for OLeo and OLeocorrected for alveolar volume (OLeo/VA)were based
on a study performed in our laboratory in 103healthy Dutch children (21).
Inhalation provocation was carried out with aerosolized methacho-
line bromide and sodium metabisulfite (NazSzOs, buffered to pH 7.4
by adding phosphate buffer). MCH was given in doubling concentra-
tions of 0.15 to 39.2 mg/ml, MBS in doubling concentrations of 2 to
256 mg/ml as described previously (22). The aerosols were generated
by a calibrated De Vilbiss 66 Nebulizer (De Vilbiss Co., Somerset, PA),
with closed vent, attached to a French-Rosenthal dosimeter (Labora-
tory for Applied Immunology, Baltimore, MO) driven by air at 138kPa.
The children were instructed to inspire slowly and as deeply as possible.
During inspiration the dosimeter was triggered for 0.6 s. After full in-
spiration, breath was held for 5 s. A total of 20 J.l.1 of aerosol was deliv-
ered to the mouth in 4 consecutive breaths. Mouth doses were 3 to 784
ug for MCH, and 40 to 5,120 ug for MBS. Provocations with MCH
and MBS were preceded by inhalation of normal saline. The interval
between consecutive doses was 3 min. FEV I was measured in triplicate
after each dose-step until the best value had fallen from baseline by at
least 20%. The provocativedose that resulted in a 20% fall in FEV I (POzo)
was calculated by interpolation of the dose-response curve on a log-
linear scale.
All lung function tests were performed with subjects in sitting posi-
tion. All volumes werecorrected to BTPS conditions. The equipment and
procedures werein accordance with international recommendations (23,
24).
Data Analysis
Where two control patients were available for a CDH patient, the mean
value of two matched controls was used for paired analysis of the differ-
ences between CDH patients and controls. In the few cases where only
one control patient was available, the data of this control patient were
used. To exclude the influence of prematurity and atopy as confound-
ing factors, separate analysis of data was performed after excluding all
prematurely born infants, and after exclusion of all atopic children. Data
of COH patients and controls werecompared with paired t tests, or Wil-
coxon's signed-rank test if appropriate. Paired comparisons of percen-
tages were done with the Mantel-Haenszel test. Logarithmic transfor-
mation was used in all analyses of POzoMCH to approximate a normal
distribution. To evaluate the effect of age on PDzoMCH, logistic regres-
sion was performed. Because only few responded to MBS, these data
were described without further statistical analysis. The relation between
patient characteristics and lung function results was studied by least
squares regression. Multiple regression analysis for continuous outcomes
was used to study interaction between variables, i.e.,whether the magni-
tude of the difference between both groups depended on certain other
parameters. Correlation coefficients given are Spearman's. Data given
are mean ± SEM unless stated otherwise. Statistical significance was
accepted at 1% level for all tests.
RESULTS
Patient Characteristics, Questionnaire,
and Physical Examination
In the CDR group (n = 40), all patients except two had left-
sided CDR. Two patients were small for gestational age; three
children were born prematurely. Two CDR patients had only a
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* Data given are numbers of patients or median (range). Duration of oxygen supply
is expressed as the total number of days, including days of artificial ventilation.
prestudy visit in the hospital: One refused to perform the lung
function tests, the second was not able to perform lung function
tests due to neurodevelopmental impairment. The data on med-
ical history, physical examination, and the standardized ques-
tionnaire of these two CDH patients were included in the analy-
sis. 1\\'0 matched controls could be recruited for 30 CDH patients,
only one control patient could be found for five CDH patients,
while for three CDH patients no suitable control patients could
be selected. The 65 control patients had needed neonatal inten-
sive care for: meconium aspiration (n = 29), pneumonia (n =
11), persistent fetal circulation (n = 8), asphyxia (n = 6), respi-
ratory distresssyndrome (n = 7), amniotic fluid aspiration (n = 3),
and pneumothorax (n = 1). One control patient was small for
gestational age at birth, and 24 were born prematurely.
The characteristics of 38 CDH patients who performed lung
function tests and 65 control patients are shown in Table 1. The
groups were similar with respect to sex, birth weight, duration
of artificial ventilation, and duration of oxygen supply. Older
CDH patients had been ventilated shorter than younger CDH
patients (r = -0.45; p = 0.005). Mean gestational age was 39.6
wk in the CDH group which was slightly higher compared with
37.7 wk in the control group. The median maximal PIo2 was 0.5
in CDH and 0.95 in control patients (p < 0.001). Ten CDH pa-
tients underwent pressure-controlled ventilation with median
maximal inspiratory peak pressures of 37.5 em H20 (range 20
to 55 cm H20 ); all other CDH patients underwent volume-con-
trolled ventilation, and peak pressure values could not be retraced.
Median maximal inspiratory peak pressures available in 35 con-
trol patients was 35 em H20 (range 17to 55 em H20 ). Eight CDH
patients (7 term) and six control patients (3 term) fulfilled the
criteria of BPD according to Bancalari (2) (NS): They had been
ventilated within the first week of life and were still oxygen-
dependent at the age of 28 d. Eight percent of the CDH children
and 23% of control patients had a history of atopy (NS). The
family history (first and second degree) for atopy or atopic lung
disease was positive in 54070 of CDH patients and in 52% of con-
trol patients (Table 1).
At the time of assessment one CD H patient and three con-
trols were using inhaled corticosteroids. Two CDH patients and
one control were using a J32-agonist on demand. The medical his-
tory revealed lung symptoms within the last year in 11of 40 CDH
patients and 11 of 65 control patients (NS). Respiratory symp-
toms within the first three years of life were reported for 17 of
39 CDH patients and 24 of64 controls (NS). Symptoms of wheez-
ing and dyspnea during the past 12 mo were reported by 23070
of the CDH patients and 20% of controls (NS). Limitation of
exercise endurance was mentioned by 18% of the CDH group
TABLE 1
PATIENT CHARACTERISTICS·
Number
Age at follow-up, yr
Cestational age, wk
Birth weight, g
Ventilation, d
Supplemental oxygen, d
Maximal F102
Atopic history positive
Family history positive
(atopy, lung disease)
CDH
38 (21 male)
11.7 (7.4-17.6)
40 (28-43)
3,275
(1,OOO-4,3OO)
4.0 (0-49)
11.0 (0-187)
0.5 (0.21-1)
3 (8%)
20 (54%)
Control without CDH
65 (44 male)
12.1 (7.7-18.2)
38 (29-42)
2,950
(1,250-4,200)
4.3 (0-25)
10.0 (0-38)
0.95 (0.21-1)
15 (23%)
33 (52%)
and 6% of control patients (NS). Eighteen percent of CDH pa-
tients and 16% of controls had consulted a physician for respi-
ratory symptoms during the past year (NS). Two children (one
in each group) smoked themselves, whereas smoking occurred
in 62% of the households in the CDH group and in 41% of the
control group (NS). Separate analysis of all children who were
born at term resulted in similar results for all items mentioned
earlier. The median total respiratory symptom score was 0 in CDH
(range 0 to 24) and 0.8 in control patients (range 0 to 32; NS).
Physical examination showed mild funnel-shaped chest in 20070
of the CDH patients and in 12% of control patients (NS). No
wheezing was present in any of the children. Daily peak flow
registration showed a similar median variability of 4.4070 in CDH
(range 2 to 17.7%) and 4.8070 in control patients (range 1.9 to
12.9%; NS). The mean total respiratory symptom scores, the find-
ings of physical examination, and daily peak flow registrations
were not significantly different after exclusion of prematurely
born children, or after exclusion of atopic subjects.
lung Function
Analysis was performed on data from 35 CDH patients and 65
matched control patients. Spirometry showed a significantly lower
FEV I/VC in CDH compared with controls before bronchodila-
tation (Table 2; p = 0.01). Flow-volume curves showed normal
values for FVC and PEF before and after bronchodilatation in
both groups (data not shown). FEV I was significantly lower in
CDH patients compared with controls before and after bron-
chodilatation (84 ± 3 versus 95 ± 2, and 92 ± 3 versus 101 ±
2% predicted, respectively). The percentage of patients with ab-
normally low FEV I and MEF25 values « -1.96 SD from pre-
dicted) was high in both groups: FEV I was abnormal in 67070
of CDH patients and 25% of controls before bronchodilatation,
and in 47% of CDH patients and 22% of controls after bron-
chodilatation. MEF25was abnormally low in CDH before and
after bronchodilatation in 79% and 59% and in controls in 41%
and 22% respectively.After 1mg of inhaled terbutaline flow-vol-
ume curves showed a significant increase in FEV I and MEF25
both in CDH and in controls (Table 2; p < 0.001). CDH patients
and controls showed no significant differences in reversibility of
airflow obstruction (Table 2).
Body plethysmography showed a significantly higher mean
RVpleth and RV/TLCpleth in CDH than in control patients (Table
2; p = 0.001 and 0.006, respectively). SGaw was 181 ± 15%
predicted in CDH and 156 ± 12% predicted in controls (NS).
Air trapping was estimated from the difference between TLCpleth
and TLCHe: Mean trapped air was 5 ± 0.5070 of TLCpleth in
CDH and 3 ± 0.6% in controls (NS). RV/TLCHewas 26 ± 1%
in CDH and 23 ± 1070 in controls (p = 0.006). No differences
in ERV, TV, and IRV were found between the groups.
DLCO was measured in 17 matched couples and was 100 ±
3% predicted in CDH and 105 ± 2% predicted in control pa-
tients (NS). DLco/VAwas 93 ± 3% predicted in CDH and 101 ±
2% predicted in controls (NS).
Separate analysis of term born patients showed similar per-
centage of predicted values for all lung function tests. In con-
trols spirometric FEV I/VC before and after bronchodilatation
weresignificantly lower(differences of means both 5) in the atopic
children than in nonatopic children. The same was true of MEF25
(difference of means before and after bronchodilatation, respec-
tively, 14% and 24%). Abnormal MEF25was observed in 22%
of term born controls without an atopic history, irrespective of
bronchodilatation.
Airway Responsiveness
In four CDH patients and in four controls FEV I/VC was less
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TABLE 2
LUNG FUNCTION RESULTS IN CDH
AND IN MATCHED CONTROLS*
Before After
Broncho- Broncho- Change
dilatation dilatation (% pred)
Spirometry CDH FEV, 89 ± 3 96 ± 3 7 ± 1
FEV,/VC 77 ± 2t 83 ± 1
Control FEV, 96 ± 2 103 ± 2 7 ± 1
FEV,/VC 82 ± 1 86 ± 1
Flow-volume curves CDH FEV, 84 ± 3t 92 ± st 8±1
MEF25 52 ± 4t 67 ± st 16± 2
Control FEV, 95 ±2 101 ± 2 6 ± 1
MEF25 70± 4 92 ± 3 21 ± 3
Body plethysmography CDH TlC 104 ± 3
RV 125 ± st
RV/TlC 29± it
Control TlC 99± 2
RV 105 ± 3
RV/TlC 23 ± 1
Diffusion capacity CDH DLco 100± 3
DLco/VA 93 ± 3
Control DLco 10S± 2
DLco/VA 101 ± 2
* Values are mean ± SEM. All data are expressed as percentage of predicted, except
FEVdVC, and RV/TLC. Spirometry and flow-volume curves are shown before and after
inhalation of 1 mg of terbutaline, whereas body plethysmography was performed after
bronchodilation only.
t Significant difference between CDH and control patients in the same treatment
group (with or without terbutaline), p < 0.01.
than 0.7, and hence no challenge test was done. Inhalation provo-
cation was performed in 32 CDH patients and in 56 controls.
Inhalation of MCH resulted in a 20% or more decrease of FEV 1
in 56% of CDH patients and in 38% of controls (NS). The in-
dividual PD20MCH values are shown in Figure 1. PD 20MCH
< 150 ug, which is more than 2 SD below the mean value in
healthy children (25), was found in 38% of CDH patients and
in 23070 of controls (NS). Similar results were found after exclu-
sion of prematures and atopic children. The prevalence of in-
creased airway responsiveness to MBS was much lower than to
MCH: Only two CDH patients and six controls showed a 20%
or more decrease in FEV1 after inhalation of MBS. PD 20MBS
was 1,100 and 195 ug in the two CDH respondents; the median
PD 20MBSin six controls was 765 ug. After exclusion of prema-
turely born children two CDH and four control respondents were
left; after exclusion of atopic children only one respondent to
inhalation of MBS was present in each group. No difference in
the prevalence of increased responsiveness to MCH and MBS
was found between CDH patients and controls with or without
a history of atopy, and the same was true for PD20MCH and
PD20MBSin respondents. No relation between positive challenge
tests and a positive family history for lung disease or atopy was
apparent in CDH and control patients.
Correlation between lung Function Results and
Other Patient Characteristics
This analysis was performed in 38 CDH patients and 65 con-
trols. The results of the lung function tests and the prevalence
of increased airway responsiveness on the one hand, and ges-
tational age, birth weight, maximal FIo2, or parental smoking
habits on the other hand did not correlate for either group. In
CDH the duration of artificial ventilation correlated negatively
with spirometric FEV 1 before and after bronchodilatation (Fig-
ure 2), spirometric VC before and after bronchodilatation, FEV 1
and FVC in flow-volume curves after bronchodilatation, and
VCpleth. All slopes resulting from linear regression analysis of
lung function parameters against duration of ventilation in CDH
patients were between -1.0 and -1.2% predicted per day of ven-
tilation (p <0.01 in all cases), whereas no significant slopes were
found in control patients (slopes varied from - 0.3 to 0.3). In
addition, CDH patients and control were grouped according to
whether or not they had been ventilated for at least 7 d. Controls
who had been ventilated for less than 7 d had similar lung func-
tion results as those who had been ventilated for at least 7 d.
However, CDH patients who had been ventilated for 7 d or more
had significantly lower FEV1 and VC (spirometry and flow-
volume curves, before and after bronchodilatation), PEF before
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Figure 2. Relation between duration of artificial ventilation (days)
and FEV, (expressed as percentage of predicted) after bronchodila-
tation with 1 mg of inhaled terbutaline measured by spirometry in
CDH (closed circles) and controls (open circles). The regression lines
are indicated for both groups: solid line for CDH (y =103.03 - 1.12 *
ventilation; p =0.0001) and dashed line for controls (y =103.14 -
0.02 * ventilation; p = 0.97).
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Figure 1. Inhalation provocation with methacholine (MCH) in CDH
and in control patients. The provocative dose that resulted in 20%
decrease of FEV1 is indicated for MCH on a logarithmic scale. CDH
patients are shown as closed circles and controls as open circles. The
highest dose of MCH was 784 J.1g. Nonrespondents are indicated in
the box.
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Figure 3. Relation between the probability to have PD20MCH < 150
J.l.g (A) or to reach PD20MCH (8) and age at follow-up in CDH and
in control patients.
bronchodilatation, and MEF25 after bronchodilatation than
CDH patients who had been ventilated for up to 7 d. CDH pa-
tients ventilated for at least 7 d had significantly lower TLCHe,
TLCpleth, VCpleth, and higher RV/TLCp1eth than those who had
been ventilated shorter (Table 3). DLCO was 93 ± 4% predicted
in CDH patients ventilated for up to 7 d and 98 ± 4070 in those
who had been ventilated for 7 d or more (NS). Both for CDH
and control patients a negative correlation was found between
the duration of oxygen supply and FEVI and VC before and af-
ter bronchodilatation in spirometry, FVC before and after bron-
chodilatation, FEVI before bronchodilatation in flow-volume
curves, TLCpleth, TLCHe, VCpleth, and RV/TLC p1eth. Similar corre-
lations were found after exclusion of children who were born
prematurely and/or had a positive atopic history. Age at follow-
up in CDH and in controls correlated positively with PEF be-
fore and after bronchodilatation. In CDH, the probability to have
a positive response to inhalation of MCH, i.e., PD20MCH < 784
ug, correlated negatively with age (p = 0.001; Figure 3). The same
was true for the probability to have a PD20MCH < 150 ug (p =
0.004; Figure 3). No significant relation between the presence
and the magnitude of PD20MCH and age could be shown for
control patients. The relations of these parameters with age, how-
ever, did not differ significantly between the two groups. Chil-
dren who had respiratory symptoms during the first 3 yr of life
or within the last year had significantly lower FEVI/VC, FEVI
(spirometry and flow-volume curves), PEF, and MEF25 before
and after bronchodilatation compared with children without re-
spiratory symptoms. Similar results were found after exclusion
of prematures and atopic subjects.
DISCUSSION
We found mild obstructive lung function abnormalities and a
high prevalence of increased airway responsiveness to methacho-
line both in children with neonatal repair of CDH and, to a lesser
extent, in age-matched controls. The controls underwent similar
neonatal treatment but had not been operated on for CDH and
did not have lung hypoplasia. Both groups showed normal total
lung capacity and normal diffusion capacity under resting con-
ditions, suggesting that no important lung function impairment
had resulted from CDH.
Interpretation of long-term pulmonary sequelae after neonatal
repair of CDH has been difficult because of the lack of com-
parative long-term data on lung function abnormalities in venti-
lated term neonates without CDH. The present study is the first
in which lung function data of CDH patients are compared with
TABLE 3
LUNG FUNCTION IN CDH PATIENTS VENTILATED FOR
LESS THAN 7 D AND FOR 7 D OR MORE*
Parameter < 7 d (n =23) > 7 d (n = 15)
Duration of ventilation, 2 (0-6) d 16 (7-49) d
median (range)
Spirometry
FEV, before BD 98 ± 3 74± 4
FEV, after BD 105 ± 3 79± 3
VC before BD 103 ± 3 83 ± 3
Flow-volume curves
PEF before BD 100±4 80± 5
MEF25 after BD 76± 6 4B± 7
Body plethysmography
TLC 10B± 3 96± 3
RV!TLC 27 ± 1 33 ±2
* Values are mean ± SEM. All data are expressed as percentage of predicted, except
RV/TLC. Significant differences were found for all parameters (p < 0.01).
those of age-matched controls who were selected for the best pos-
sible match for gestational age, birth weight, duration of artifi-
cial ventilation and oxygen supply, and sex. Gestational age was
slightly, but significantly lower in the control group and it could
be argued that this mayexplain differences in lung function. How-
ever, mean gestational age was more than 37 wk in both groups
(37.7 versus 39.6 wk), and similar results were found after sepa-
rate analysis of term born children. Therefore differences in lung
function between the two groups can not be attributed to differ-
ences in gestational age. The maximal Flo2 was significantly lower
in CDH than in controls, but did not correlate with the mea-
sured lung function parameters. The groups were similar with
respect to atopic history, positive family history for atopy or lung
diseases, and smoking habits. Therefore, these potential con-
founding factors cannot explain differences in lung function be-
tween CDH and controls either.
We found more peripheral airway obstruction in CDH pa-
tients than in controls, as was apparent from decreased FEVI/VC
and .MEF25, high percentages of abnormal FEVh and MEF2S,
and Increased RV/TLC. In control patients mild airflow obstruc-
tion was suggested by decreased MEF25, and abnormal.Fliv, and
MEF2Sin more than 20% of cases after exclusion of the prema-
turely born and atopic children. Separate analysis of term born
children without a history of atopy indicated that in controls
FEVI/VC and MEF2S were higher in nonatopic children com-
pared with atopic children. Such a difference could not be demon-
strated for the CDH group (with only three children having a
history of atopy). There was no difference in reversibility of air-
way obstruction between the groups. The mean reversibility of
FEVI was within the normal range seen in healthy individuals
(24). Mild airflow obstruction (13, 14,26) or normal spirometry
(17) were reported in school age children before 1976. A number
of these children were operated on after the perinatal period at
ages up to 2 yr. An unspecified number were ventilated postoper-
atively. It is likely that the number was small. In patients born
subsequently, Falconer and coworkers (15) found evidence of re-
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duced expiratory flows at 500/0 VC. Seven of his 19 children had
been ventilated for 4 d or more.
Airflow obstruction has been described in several follow-up
studies of premature children with and without BPD (3-5,9,27),
but normal spirometric results have also been reported (8). The
airflow obstruction described in nonventilated CDH patients sug-
gests residual hypoplasia of lungs or airways. Abnormal tracheal
or bronchial cartilage has been described in CDH (28). This may
enhance airflow obstruction as a result of inadequate support,
and, hence, dynamic compression of the intrathoracic airway dur-
ing forced expiration. In addition, functional impairment may
have resulted from airway damage due to artificial ventilation
and oxygen treatment in ventilated CDH patients.
TLC and VC were normal in our study, consistent with the
observations of others (13, 14), although restrictive defects have
also been observed (29). Residual volume was marginally elevated
in our study in that of Reid and Hutcherson (29).
Normal TLC and VC in CDH suggest that absence of resid-
uallung hypoplasia and it may well be that the compensatory
lung growth takes place during the first year of life (30). How-
ever, the number of alveoli may still be reduced. Therefore we
also measured diffusion capacity, which is a measure of the diffu-
sion surface and consequently of the alveolar surface. DLco and
DLCO corrected for alveolar volume were normal in CDH and
in control patients. This suggests the presence of a normal diffu-
sion surface area under resting conditions at long-term follow-
up in CDH, as described previously (14). Exercise stress testing
with measurement of DLco would be necessary to reveal the func-
tional significance of a possible residual lung hypoplasia. In fa-
vor of residual lung hypoplasia are mild airflow obstruction,
decreased lung perfusion on the ipsilateral side of the diaphrag-
matic defect (14, 16,29), the observation that anatomic forma-
tion of further generations of airways and conducting vessels
does not develop after 16 wk gestation (31), and findings of long-
term lung morphology after neonatal repair of CDH: Normal
total lung volume, but an abnormal lung structure, has been de-
scribed in three cases of CDH at autopsy after 2.5 to 64 mo (32,
33). Whereas the total number of alveoli was either decreased
(32, 33) or normal (33), the alveolar size was increased in all cases,
especially on the ipsilateral side. The lower DLCO/VA in our CDH
patients compared with controls may indicate persistence of such
morphologic abnormalities. The normal DLco in CDH patients
and in age-matched ventilated controls suggests that diffusion
capacity is not severely affected by lung damage caused by ar-
tificial ventilation.
There are no data on airway responsiveness at long-term fol-
low-up in children with CDH. We found a high prevalence of
MCH responsiveness both in CDH (56%) and in control patients
(38%), irrespective of an atopic history or a positive family his-
tory for atopy or lung disease. Several investigators have described
increased airway responsiveness to inhalation of MCH or hista-
mine in prematures following artificial ventilation (5, 6, 27). A
high prevalence of exercise-induced bronchospasm was found
in a group of term born children with meconium aspiration syn-
drome following a short period of artificial ventilation (34). The
high prevalence of increased airway responsiveness to MCH, to-
gether with the smaller number of positive respondents after in-
halation of MBS, suggests that the mechanism of airway nar-
rowing in our patients is different from that in asthmatic subjects
where both challenges correlate well (35). Residual structural nar-
rowing of distal airways or airway smooth muscle hypertrophy
may explain our findings, because these abnormalities would lead
to increased airway responsiveness only as a result of the altered
airway geometry (36). Because no differences were found between
CDH patients and controls, it can be assumed that artificial ven-
tilation during the neonatal period is a more likely cause of these
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abnormalities than lung or airway hypoplasia in CDH. We found
that the prevalence of airway responsiveness to MCH was sig-
nificantly lower in older CDH patients. This may reflect the nat-
ural history of airway responsiveness following artificial venti-
lation in the neonatal period, although our cross-sectional data
do not allow for this assumption. Another possible explanation
is that older patients had been artificially ventilated for a shorter
period of time because of the restricted intensive care treatment
in those days. Therefore CDH patients born earlier, e.g., between
1975and 1980,and who survived their neonatal period, may have
had less severe lung hypoplasia with less structural small airway
abnormalities than the children who were born later.
We found a negative correlation between the duration of ven-
tilation and FEV1 at follow-up in CDH. A negative correlation
between FEV 1 and duration of ventilation has been described
in follow-up studies of prematures as well (4, 9). Previous studies
in ventilated prematures without BPD suggest that the effect of
artificial ventilation is independent of gestational age (8, 9). How-
ever, most prematures with very low birth weight will require ar-
tificial ventilation for a longer period of time and are more likely
to develop BPD (2). A high incidence of BPD in CDH patients
has been reported by Bos and coworkers (12)who studied a group
of CDH survivors born between 1980 and 1989 with respiratory
insufficiency within the first 6 h after birth. The children in our
study group were born between 1975 and 1986 when extracor-
poreal membrane oxygenation and high-frequency oscillatory
ventilation were not available. It can be assumed that especially
CDH patients with less severe lung hypoplasia survived at that
time, whereas the children with severe lung hypoplasia and se-
vere persistent pulmonary hypertension may have died even be-
fore reaching the Pediatric Surgical Intensive Care Unit. This as-
sumption is supported by the fact that our group of CDH patients
had a median duration of ventilation of only 4 d with a mean
maximal F102 of 0.5. That we found lung function abnormali-
ties especially in CDH patients who were ventilated for at least
7 d suggests that respiratory morbidity may well increase in those
children with more severe lung hypoplasia, who will require ar-
tificial ventilation for longer periods of time and who presently
survive CDH (3, 8, 9).
In conclusion, we found mild obstructive lung function ab-
normalities in CDH and also, but to a lesser extent, in carefully
matched control patients. The difference between CDH patients
and controls could not be explained by differences in patient char-
acteristics and could therefore be due to residual lung hypopla-
sia, and/or to anatomic and functional changes of the thoracic
wall, the diaphragm, or the airway cartilage in the CDH patients.
CDH patients showed no important reduction of lung volume
and diffusion capacity under resting conditions. Airway respon-
siveness to MCH, but not to MBS, was increased in both groups,
suggesting that the mechanism of airway narrowing was differ-
ent from that in asthmatics. We speculate that structural abnor-
malities in distal airways are responsible for the high incidence
of increased airway responsiveness. Our data suggest that not
only residual lung hypoplasia, but also neonatal intensive care
treatment contribute to the persisting airway obstruction and in-
creased airway responsiveness in CDH patients.
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